JP2023553490A5 - - Google Patents
Info
- Publication number
- JP2023553490A5 JP2023553490A5 JP2023536049A JP2023536049A JP2023553490A5 JP 2023553490 A5 JP2023553490 A5 JP 2023553490A5 JP 2023536049 A JP2023536049 A JP 2023536049A JP 2023536049 A JP2023536049 A JP 2023536049A JP 2023553490 A5 JP2023553490 A5 JP 2023553490A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- expression
- repressor
- expression repressor
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063125833P | 2020-12-15 | 2020-12-15 | |
| US63/125,833 | 2020-12-15 | ||
| US202163137097P | 2021-01-13 | 2021-01-13 | |
| US63/137,097 | 2021-01-13 | ||
| US202163212991P | 2021-06-21 | 2021-06-21 | |
| US63/212,991 | 2021-06-21 | ||
| US202163281022P | 2021-11-18 | 2021-11-18 | |
| US63/281,022 | 2021-11-18 | ||
| PCT/US2021/010059 WO2022132195A2 (en) | 2020-12-15 | 2021-12-15 | Compositions and methods for modulation myc expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023553490A JP2023553490A (ja) | 2023-12-21 |
| JP2023553490A5 true JP2023553490A5 (https=) | 2024-12-23 |
Family
ID=82060102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023536049A Pending JP2023553490A (ja) | 2020-12-15 | 2021-12-15 | Ｍｙｃ発現を調節するための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240132559A1 (https=) |
| EP (1) | EP4262849A4 (https=) |
| JP (1) | JP2023553490A (https=) |
| KR (1) | KR20230120138A (https=) |
| AU (1) | AU2021401231A1 (https=) |
| CA (1) | CA3205133A1 (https=) |
| MX (1) | MX2023007116A (https=) |
| WO (1) | WO2022132195A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190255106A1 (en) | 2016-09-07 | 2019-08-22 | Flagship Pioneering Inc. | Methods and compositions for modulating gene expression |
| CN115192714B (zh) * | 2022-07-08 | 2024-09-17 | 沈阳药科大学 | Hdac6抑制剂在制备治疗dnmt3a基因缺失癌症的药物中的用途 |
| TW202417012A (zh) * | 2022-08-19 | 2024-05-01 | 美商旗艦先鋒創新公司 | 包含myc調節劑及檢查點抑制劑之組合療法 |
| WO2024238723A1 (en) | 2023-05-16 | 2024-11-21 | Omega Therapeutics, Inc. | Methods and compositions for modulating pcsk9 expression |
| EP4713027A1 (en) | 2023-05-16 | 2026-03-25 | Omega Therapeutics, Inc. | Methods and compositions for modulating methylation of a target gene |
| EP4716741A2 (en) * | 2023-05-23 | 2026-04-01 | Flagship Labs 114, Inc. | Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression |
| WO2025019742A1 (en) | 2023-07-19 | 2025-01-23 | Omega Therapeutics, Inc. | Methods and compositions for modulating ctnnb1 expression |
| WO2025064469A1 (en) * | 2023-09-18 | 2025-03-27 | Omega Therapeutics, Inc. | Methods for assessing dosage for epigenetic modifying agents |
| WO2025144907A1 (en) * | 2023-12-27 | 2025-07-03 | Flagship Pioneering Innovations V, Inc. | Kinase inhibitors and particles comprising myc modulators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997011972A1 (en) * | 1995-09-28 | 1997-04-03 | The Trustees Of Columbia University In The City Of New York | Chimeric dna-binding/dna methyltransferase nucleic acid and polypeptide and uses thereof |
| GB201119904D0 (en) * | 2011-11-17 | 2011-12-28 | Univ Vilnius | Analysis of methylation sites |
| EP3237017A4 (en) * | 2014-12-24 | 2018-08-01 | Dana-Farber Cancer Institute, Inc. | Systems and methods for genome modification and regulation |
| KR101900278B1 (ko) * | 2016-04-18 | 2018-09-19 | 건국대학교 글로컬산학협력단 | Myc-ap4 축 활성화된 암의 예방 또는 치료용 조성물의 스크리닝 방법 |
| US20200149039A1 (en) * | 2016-12-12 | 2020-05-14 | Whitehead Institute For Biomedical Research | Regulation of transcription through ctcf loop anchors |
| CN110678548A (zh) * | 2017-03-31 | 2020-01-10 | 埃吉诺维亚公司 | 抗病毒治疗剂 |
| US20190233805A1 (en) * | 2017-10-04 | 2019-08-01 | The Regents Of The University Of California | Targetable proteins for epigenetic modification and methods for use thereof |
| US20220380760A1 (en) * | 2018-10-15 | 2022-12-01 | Flagship Pioneering Innovations V, Inc. | Disrupting genomic complex assembly in fusion genes |
| US11866469B2 (en) * | 2019-02-06 | 2024-01-09 | Klogenix Llc | DNA binding proteins and uses thereof |
-
2021
- 2021-12-15 CA CA3205133A patent/CA3205133A1/en active Pending
- 2021-12-15 MX MX2023007116A patent/MX2023007116A/es unknown
- 2021-12-15 EP EP21907332.7A patent/EP4262849A4/en active Pending
- 2021-12-15 AU AU2021401231A patent/AU2021401231A1/en active Pending
- 2021-12-15 US US18/257,483 patent/US20240132559A1/en active Pending
- 2021-12-15 WO PCT/US2021/010059 patent/WO2022132195A2/en not_active Ceased
- 2021-12-15 JP JP2023536049A patent/JP2023553490A/ja active Pending
- 2021-12-15 KR KR1020237024060A patent/KR20230120138A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023553490A5 (https=) | ||
| Matchett et al. | Ran GTPase in nuclear envelope formation and cancer metastasis | |
| JP7409612B2 (ja) | トリパタイトモチーフ含有蛋白質１６（ｔｒｉｍ１６）シグナル伝達を誘導するための組成物及び方法 | |
| US10071129B2 (en) | Method for identifying bromodomain inhibitors | |
| CN110917352A (zh) | Rock抑制剂在肿瘤免疫治疗中的新用法 | |
| AU2024259837B2 (en) | ADP-ribose binding peptide having anticancer activity and use thereof | |
| Larsen et al. | From DNA damage to G~ 2 arrest: The many roles of topoisomerase II | |
| JP2017014185A (ja) | 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物 | |
| Graziano et al. | Mechanisms of oncogene-induced genomic instability | |
| Wang et al. | Cancer‐derived IgG involved in cisplatin resistance through PTP‐BAS/Src/PDK1/AKT signaling pathway | |
| JP2023513468A (ja) | 疾患の治療のための方法及び組成物 | |
| KR20190040824A (ko) | CRISP/Cas 시스템에 사용하기 위한 융합 단백질, 그를 포함하는 복합체 및 그의 용도 | |
| CN108410878B (zh) | 一种lrpprc特异性核酸适配体及其应用 | |
| KR102618932B1 (ko) | Runx3 단백질 및 CDK4 억제제 또는 mTOR 억제제 병행 투여를 포함하는 암의 예방 또는 치료를 위한 약학적 조성물 | |
| JP2017226626A (ja) | 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物 | |
| Zhang et al. | BRD4 protein as a target for lung cancer and hematological cancer therapy: a review | |
| KR102576855B1 (ko) | Tsp1을 유효성분으로 포함하는 간암의 예방 또는 치료용 조성물 | |
| Shanmugam et al. | Role of NF-κB in tumorigenesis | |
| US9145554B2 (en) | Cancer therapy method | |
| US20220064238A1 (en) | Methods And Compositions For Modifying Transcription Factor Activity by Targeting The Human Mediator Complex Using Cell Penetrating Memetic Peptides And Methods of Treating Cancer Using The Same | |
| TW201628630A (zh) | 細胞死亡誘導劑、細胞增殖抑制劑及起因於細胞增殖異常之疾病治療用醫藥組合物 | |
| US20250066420A1 (en) | Pd-l1 inhibitory peptide for cancer immunotherapy | |
| US20190030126A1 (en) | Inhibitors of the Interaction BCL-2 L10 / IP3 Receptors | |
| CN117801064A (zh) | 一种多肽、药物和用途 | |
| HK40130287A (zh) | Lincrna-p21和其用途 |